logo-loader
RNS
Science Group PLC

Science Group PLC - Executive Chair Share Purchase

RNS Number : 3644C
Science Group PLC
27 March 2025
 

 

27 March 2025

 

Science Group plc

(the "Company" or "Science Group")

 

Executive Chair Share Purchase

 

Science Group plc (AIM:SAG) announces that it has been notified by Martyn Ratcliffe, Executive Chair of the Company that on 26 March 2025 he purchased 10,000 ordinary shares of 1p each in the Company at a price of 436 pence per share for his SIPP.

 

Following this purchase, Martyn Ratcliffe has an interest in 9,482,080 ordinary shares in the Company (being approximately 21.24% of the issued share capital excluding treasury shares).  This holding comprises 9,412,080 shares held directly and 70,000 shares held in his SIPP.

 

All other Directors' beneficial interests in the share capital of the Company remain unchanged and as previously announced. 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.      

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Martyn Ratcliffe

2.      

Reason for the notification

a)

Position/status: Executive Chair

b)

Initial notification/Amendment:  Initial notification

3.      

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Science Group plc

b)

LEI: 2138009OJQT79BDB3E93

4.      

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary shares of 1p each.

Identification code: GB00B39GTJ17

b)

Nature of the transaction: Purchase of shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

436p

10,000

d)

Aggregated information:

·      Aggregated volume: 10,000

·      Price: £43,600

e)

Date of the transaction:  2025-03-26

f)

Place of the transaction: AIMX

 

 

- Ends -

 

 

For further information:

Science Group plc


Sarah Cole, Company Secretary

Tel: +44 (0) 1223 875 200

 

www.sciencegroup.com  

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)


Simon Bridges, Andrew Potts

Tel: +44 (0) 20 7523 8000



Liberum Capital Limited (Joint Broker)


Max Jones, John More

Tel: +44 (0) 20 3100 2000


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZGZFNVLGKZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Transaction in Own Shares

3 days, 5 hours ago

Holding(s) in Company

1 week, 3 days ago

Transaction in Own Shares

1 week, 3 days ago

Change to buyback reporting

2 weeks, 3 days ago

Total Voting Rights

2 weeks, 3 days ago

Transaction in Own Shares

3 weeks, 1 day ago

Transaction in Own Shares

3 weeks, 2 days ago

3 min read